R-406

R-406

SCHEMBL12903997

[2H]C([2H])([2H])Oc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SYK

The experimentally established mechanism targets of R-406. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK known ✓ P43405 14/20 0.92
PTK2 Q05397 3/20 0.92
EGFR P00533 3/20 0.92
ADORA3 P0DMS8 2/20 0.92
TYRO3 Q06418 2/20 0.92
PLK4 O00444 2/20 0.92
AURKA O14965 2/20 0.92
STK16 O75716 2/20 0.92
RET P07949 2/20 0.92
FLT3 P36888 2/20 0.92
MAPK8 P45983 2/20 0.92
MAPK9 P45984 2/20 0.92
MST1R Q04912 2/20 0.92
TNK1 Q13470 2/20 0.92
IKBKE Q14164 2/20 0.92
MAP3K11 Q16584 2/20 0.92
ADCK1 Q86TW2 2/20 0.92
PIP4K2C Q8TBX8 2/20 0.92
NEK9 Q8TD19 2/20 0.92
AURKB Q96GD4 2/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
R-406 SCHEMBL12904000 0.98 SYK (0.89) SYKPTK2EGFRADORA3TYRO3
R-406 SCHEMBL12903982 0.98 SYK (0.91) SYKPTK2EGFRADORA3TYRO3
R-406 SCHEMBL12903973 0.97 SYK (0.86) SYKPTK2EGFRADORA3TYRO3
R-406 SCHEMBL29358236 0.96 SYK (1.00) SYKPTK2EGFRADORA3TYRO3
R-406 SCHEMBL1200144 0.96 SYK (1.00) SYKPTK2EGFRADORA3TYRO3
SCHEMBL12903953 0.95 SYK (0.82) SYKPTK2EGFRADORA3TYRO3
SCHEMBL12903946 0.93 SYK (0.82) SYKPTK2EGFRADORA3TYRO3
SCHEMBL12903945 0.92 SYK (0.78) SYKPTK2EGFRADORA3TYRO3
SCHEMBL2627469 0.91 SYK (0.91) SYKPTK2EGFRADORA3TYRO3
SCHEMBL1383686 0.91 SYK (0.89) SYKPTK2EGFRADORA3TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015155-A1 Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015155-A1 Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses DPYD, DUT, TYMP SYK 2772/4885PTK2 4236/4885EGFR 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.